SEARCH

SEARCH BY CITATION

References

  • 1
    Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 708.
  • 2
    Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295308.
  • 3
    Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 51927.
  • 4
    Licar A, Cerkovnik P, Ocvirk J, Novakovic S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol 2010; 36: 113744.
  • 5
    Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009; 205: 85862.
  • 6
    Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, Stenzinger A, Joos H, Landt O, Heiser V, Röcken C, Dietel M. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010; 12: 3542.
  • 7
    Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittorn R, Hantel A, Benson AB 3rd, Goldberg RM et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009; 15: 73229.
  • 8
    Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 46674.
  • 9
    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 33745.
  • 10
    Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 20408.
  • 11
    Van Cutsem E. Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer. Clin Colorectal Cancer 2007; 6 Suppl 2: S605.
  • 12
    Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 2010; 17: 116876.
  • 13
    Bjørheim J, Lystad S, Lindblom A, Kressner U, Westring S, Wahlberg S, Lindmark G, Gaudernack G, Ekstrøm P, Røe J, Thilly WG, Børresen-Dale AL. Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction. Mutat Res 1998; 403: 10312.
  • 14
    Lin SY, Chen PH, Wang CK, Liu JD, Siauw CP, Chen YJ, Yang MJ, Liu MH, Chen TC, Chang JG. Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. Am J Clin Pathol 1993; 100: 6869.
  • 15
    Lleonart ME, Ramon y Cajal S, Groopman JD, Friesen MD. Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Res 2004; 32: e53.
  • 16
    McKinzie PB, Parsons BL. Detection of rare K-ras codon 12 mutations using allele-spcific competitive blocker PCR. Mutat Res 2002; 517: 20920.
  • 17
    Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider-Stock R. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 2007; 203: 48997.
  • 18
    Taback B, Bilchik AJ, Saha S, Nakayama T, Wiese DA, Turner RR, Kuo CT, Hoon DS. Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer 2004; 111: 40914.
  • 19
    van Heek NT, Clayton SJ, Sturm PD, Walker J, Gouma DJ, Noorduyn LA, Offerhaus GJ, Fox JC. Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses. J Clin Pathol 2005; 58: 131520.
  • 20
    Chang YS, Yeh KT, Chang TJ, Chai C, Lu HC, Hsu NC, Chang JG. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 2009; 9: 179.
  • 21
    Schewe C, Speich N, Sotlar K, Zimmermann D, Bollmann M, Bültmann B, Zimmermann-Dours MT, Dietel M, Petersen I. Inter-Laboratory Validation of PCR-Based HPV Detection in Pathology Specimens (QuIP). Pathol Res Pract 2006; 202: 2356.
  • 22
    Petersen I, Schewe C, Schluns K, Dietel M, Speich N, Schmitt C, Bollmann M, Sotlar K, Bultmann B, Dours-Zimmermann MT, Padberg B, Zimmermann DR. Inter-laboratory validation of PCR-based HPV detection in pathology specimens. Virchows Arch 2007; 451: 70116.
  • 23
    Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009; 35: 26271.
  • 24
    Gao J, Li YY, Sun PN, Shen L. Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. World J Gastroenterol 2010; 16: 485864.
  • 25
    Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A, Messersmith WA. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010; 12: 4350.
  • 26
    El-Maarri O. SIRPH analysis: SNuPE with IP-RP-HPLC for quantitative measurements of DNA methylation at specific CpG sites. Methods Mol Biol 2004; 287: 195205.
  • 27
    Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005; 7: 41321.
  • 28
    Carotenuto P, Roma C, Rachiglio AM, Tatangelo F, Pinto C, Ciardiello F, Nappi O, Iaffaioli RV, Botti G, Normanno N. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 2010; 11: 116979.
  • 29
    Do H, Dobrovic A. Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer 2009; 8: 82.